SEP 02, 2019 12:47 PM PDT

Drug Reduces Heart Attacks in Diabetic Patients

WRITTEN BY: Nouran Amin

Recent results from a clinical trial that evaluated the addition of a drug called ‘ticagrelor’ to aspirin were shown to improve clinical outcomes for patients with stable coronary artery disease and diabetes mellitus. These patients in the study had no history of heart attack or stroke.

Findings from the clinical trial known as ‘The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS), explained how the usage of ticagrelor with aspirin formed a dual-antiplatelet therapy that has reduced the risk of cardiovascular death, heart attack, and stroke. However, the study did show that patients on the dual therapy also experienced a greater risk of a major bleed and intracranial hemorrhage, particularly through an increased number of non-procedural subdural bleeds, in comparison to those who were on the placebo.

"With prolonged dual-antiplatelet therapy, we need to be thoughtful in considering which patients are most suited to taking the regimen -- that is, those at high ischemic risk and low bleeding risk," said THEMIS co-chair Deepak L. Bhatt, MD, MPH, executive director of Interventional Cardiovascular Programs at the Brigham and professor of medicine at Harvard Medical School. "Our findings show that the greatest benefit occurred in those patients with diabetes and stable coronary artery disease with a history of prior stenting for whom ticagrelor, when added to aspirin, reduced important cardiovascular events, such as heart attacks, strokes and amputations."

THEMIS is the largest clinical trial study involving diabetic patients to date with more than 19,000 participants who have stable coronary artery disease and diabetes that were randomly selected to receive either ticagrelor plus aspirin (the dual antiplatelet therapy) or a placebo plus aspirin. These patients were studied over the course of three years

"The THEMIS population is a critically important one in which to understand the potential benefits of taking ticagrelor in addition to aspirin. As the number of people with diabetes continues to rise globally, we need to evaluate ways of improving long-term outcomes and preventing cardiovascular and ischemic events,” says THEMIS co-chair Philippe Gabriel Steg, MD, Chief of Cardiology at Hôpital Bichat, Greater Paris University Hospitals.

Learn more about the heart disease-diabetes connection:

 

 

"Our results indicate that among those with diabetes and stable coronary artery disease, we should focus on ticagrelor for patients with a history of prior stenting. This is an easily identifiable, logical sub-group," said Bhatt. "Studies currently support using long-term dual antiplatelet therapy for patients with the acute coronary syndrome who are at high ischemic risk but low bleeding risk. Our work suggests that a much broader population of patients with stable coronary artery disease and diabetes stand to benefit substantially."

Source: Science Daily

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 04, 2021
Infographics
All You Need to Know about COVID-19 Vaccines
MAR 04, 2021
All You Need to Know about COVID-19 Vaccines
After over a year lockdowns brought on by the pandemic, hopes for returning to something even similar to ' ...
MAR 03, 2021
Drug Discovery & Development
Keeping HIV Latent
MAR 03, 2021
Keeping HIV Latent
When (HIV) human immunodeficiency virus infects cells, it can go to sleep as opposed to make viral copies of itself&mdas ...
APR 03, 2021
Drug Discovery & Development
Why Are Some Cancer Therapeutics Ineffective?
APR 03, 2021
Why Are Some Cancer Therapeutics Ineffective?
Why don’t some cancer therapeutics not work in humans when they were successful in mice? The answer to this questi ...
MAY 13, 2021
Immunology
Salmonella Vaccine Uses "Molecular Telephones" to Talk to the Immune System
MAY 13, 2021
Salmonella Vaccine Uses "Molecular Telephones" to Talk to the Immune System
Salmonella infections are a massive problem—Over 95 million people are affected by this foodborne illness every ye ...
MAY 15, 2021
Drug Discovery & Development
New Drug Blocks Critical Step in Malaria Life Cycle
MAY 15, 2021
New Drug Blocks Critical Step in Malaria Life Cycle
According to the World Health Organization (WHO), in 2019, there were approximately 229 million cases of malaria around ...
JUN 09, 2021
Cell & Molecular Biology
Mechanism Linking Neurodegeneration & Brain Injury May Open Treatment Options
JUN 09, 2021
Mechanism Linking Neurodegeneration & Brain Injury May Open Treatment Options
Studies have shown that there is a link between blows to the head and neurodegeneration. Repeated head trauma is associa ...
Loading Comments...